Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT00368537

Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections

Conditions: Skin Diseases, Bacterial

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE4
Enrollment: 550
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Location: Scottsdale Arizona

Summary

The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicated skin and/or skin structure infection (cSSSI).

Eligibility Criteria

Inclusion Criteria: * Clinical diagnosis of complicated skin or skin structure infection * Male or female, 18 years or older * Need for intravenous treatment for 4 to 14 days Exclusion Criteria: * Skin infection that can be treated by surgery \& wound care alone * Diabetic foot ulcers or bedsores where the infection is present longer than 1 week * Poor circulation such that amputation of the infected site is likely within a month Other exclusions apply

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT00368537). StuddyBuddy aggregates publicly available trial information.